Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926467 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
A Phase 2 study of Pancreatic Adenocarcinoma, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04926467 is a Phase 2 study of Pancreatic Adenocarcinoma that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 24 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04926467, a Phase 2 study of Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.
Conditions Studied
Interventions
- DRUG Anakinra
Study Locations (1)
Texas
- Baylor University Medical Center, Charles A Sammons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-07-23 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04926467
The ClinicalTrials.gov registry entry for NCT04926467 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Anakinra is the first listed.
NCT04926467 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04926467 about?
NCT04926467 is a clinical study titled "Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)". Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (wi...
What is the current status of trial NCT04926467?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-07-23. Estimated completion is 2027-06.
What conditions does trial NCT04926467 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04926467?
The interventions under investigation include: Anakinra (DRUG).
Who is sponsoring clinical trial NCT04926467?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04926467 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.